ZS, Seven Bridges | May 07, 2021
ZS and Seven Bridges disclosed a collaboration today that will merge ZS's experience in biomedical testing facilities and data science with Seven Bridges' technology platform, which enables multi-omics analytics through the translational and clinical continuum. The hybrid offers biopharmaceutical and biotechnology firms a one-stop-shop for multi-omics analysis innovation and scalability. ZS and Seven Bridges work together to help clients produce breakthrough science, promote drug development, and improve the probability of approval for potential drug candidates.
"Working side by side with our clients to help streamline R&D data and maximize pace and market to enhance patients' lives is at the heart of what we do at ZS," said Aaron Mitchell, principal, and leader of ZS's research and development excellence program. "Our collaboration with Seven Bridges allows our clients, and eventually patients, to gain access to new therapies and diagnostics more quickly."
"Drug discovery, translational medicine, and preclinical drug research all require study at the molecular and genomic levels of implementation, and our collaboration with Seven Bridges provides our clients with a new option for innovation and scalable capacity," said John Piccone, principal, and leader of ZS's biomedical research service line.
"We are building a talent pool of molecular natives with a strong knowledge of chemistry, data science, and technology to collaborate with our clients in the discovery of potential drug targets, the selection of drug candidates, and the solution of key translational medicine challenges. The integration of the Seven Bridges Platform and experts with the ZS consulting teams results in a modular approach for clients with growing multi-omics data and analytics requirements."
"We are delighted to be combining the Seven Bridges platform with ZS's innovative apps for drug discovery and translational medicine. Integrating our multi-omics analysis platform and ARIATM, a centralized solution for molecular and patient-level phenotypic analysis at scale, with their research data lake is a critical requirement for ZS's pharmaceutical clients "said Bruce Press, Seven Bridges' Chief Revenue Officer.
About Seven Bridges
Seven Bridges allows researchers to derive meaningful insights from genomic and phenotypic data, thereby advancing precision medicine. A compliant analytic platform, intelligently curated content, innovative algorithms, unmatched access to federated data sets, and specialist on-demand technical resources comprise the Seven Bridges Ecosystem. Researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical institutions are using this systematic approach to bioinformatics to maximize R&D effectiveness, improve hypothesis resolution, isolate vital biomarkers, and even transform a failing clinical trial around while also minimizing computational workflow times and data storage costs.
HealthITAnalytics | October 21, 2019
The All of Us Research Program has selected the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama to examine the use of DNA sequencing, genomics, and precision medicine for patient care. The National Center for Advancing Translational Sciences (NCATS) is funding the project, providing $7 million over the course of one year. Investigators will test cutting-edge DNA sequencing technologies that could improve diagnosis and treatment of rare and common diseases. HudsonAlpha will leverage long-read whole genome sequencing technologies to generate genetic data on about 6,000 participants from diverse backgrounds. Long-read sequencing analyzes DNA in larger segments than standard sequencing technologies and can expose genetic variations that may have otherwise gone undetected. These variations could include alterations to genetic structure, such as duplication, deletion, or rearrangement of the building blocks that make up one’s genome. Researchers are increasingly learning about how some genetic variants underlie certain health conditions or increase disease resistance. With long-read DNA sequencing, investigators will better understand the genetic underpinnings of health and disease and identify more targeted treatments in the future.